- Cowen & Co. has reiterated its Buy rating for Editas Medicine, highlighting its potential in the genome editing space.
- The company’s lead candidate, EDIT-401, shows compelling preclinical data as a potential one-time treatment for hyperlipidemia.
- Editas Medicine is conducting a public offering to raise approximately $125.00 million in gross proceeds to fund its ongoing research and development.
On May 27, 2026, analyst firm Cowen & Co. maintained its Buy rating for Editas Medicine (NASDAQ: EDIT), with the stock priced at $3.68. Editas Medicine is a clinical-stage genome editing company. It focuses on developing treatments for a range of serious diseases by correcting disease-causing genes.
The firm’s positive rating is supported by compelling preclinical data for Editas’s lead candidate, EDIT-401. As highlighted by GlobeNewswire, data presented at the 94th European Atherosclerosis Society Congress showed significant results. A single dose in non-human primates caused mean reductions of approximately 90% or greater in LDL-cholesterol and other harmful lipids, underscoring the potential of this gene therapy.
Further data from the American Society of Gene and Cell Therapy 2026 Annual Meeting supports EDIT-401 as a potential one-time treatment for hyperlipidemia. This is a condition where there are high levels of fats, like cholesterol, in the blood. Editas expects to submit a Clinical Trial Notification for EDIT-401 by mid-2026, moving closer to human trials for this innovative biotechnology stock.
To fund its research, Editas announced a public offering to raise capital. The company is selling over 55.50 million shares of its common stock. Each share is sold with an accompanying warrant at a combined price of $2.25, with the goal of raising approximately $125.00 million in gross proceeds.
The offering also includes warrants to purchase an additional 55.50 million shares. A warrant gives an investor the right, but not the obligation, to buy a stock at a set price before a specific date. If all warrants are exercised, Editas could raise an additional $194.40 million.
